- Home
- REPL vs WIW Comparison
REPL vs WIW Comparison
Compare REPL & WIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- WIW
- Stock Information
- Founded
- REPL 2015
- WIW 2004
- Country
- REPL United States
- WIW United States
- Employees
- REPL N/A
- WIW N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- WIW Finance Companies
- Sector
- REPL Health Care
- WIW Finance
- Exchange
- REPL Nasdaq
- WIW Nasdaq
- Market Cap
- REPL 547.0M
- WIW 536.0M
- IPO Year
- REPL 2018
- WIW N/A
- Fundamental
- Price
- REPL $5.56
- WIW $8.80
- Analyst Decision
- REPL Buy
- WIW
- Analyst Count
- REPL 10
- WIW 0
- Target Price
- REPL $8.25
- WIW N/A
- AVG Volume (30 Days)
- REPL 24.2M
- WIW 229.9K
- Earning Date
- REPL 08-07-2025
- WIW 01-01-0001
- Dividend Yield
- REPL N/A
- WIW 11.14%
- EPS Growth
- REPL N/A
- WIW N/A
- EPS
- REPL N/A
- WIW N/A
- Revenue
- REPL N/A
- WIW N/A
- Revenue This Year
- REPL N/A
- WIW N/A
- Revenue Next Year
- REPL $194.05
- WIW N/A
- P/E Ratio
- REPL N/A
- WIW N/A
- Revenue Growth
- REPL N/A
- WIW N/A
- 52 Week Low
- REPL $2.68
- WIW $8.01
- 52 Week High
- REPL $17.00
- WIW $9.37
- Technical
- Relative Strength Index (RSI)
- REPL 44.05
- WIW 52.60
- Support Level
- REPL $4.49
- WIW $8.78
- Resistance Level
- REPL $6.39
- WIW $8.87
- Average True Range (ATR)
- REPL 0.77
- WIW 0.05
- MACD
- REPL 0.09
- WIW 0.00
- Stochastic Oscillator
- REPL 48.77
- WIW 53.13
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.